Notice: This company has been marked as potentially delisted and may not be actively trading. Akers Biosciences (AKER) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends AKER vs. VNRX, CDIO, ICCC, OCX, AWH, TRIB, BMRA, VRAX, TNFA, and MYMDShould you be buying Akers Biosciences stock or one of its competitors? The main competitors of Akers Biosciences include VolitionRx (VNRX), Cardio Diagnostics (CDIO), ImmuCell (ICCC), OncoCyte (OCX), Aspira Women's Health (AWH), Trinity Biotech (TRIB), Biomerica (BMRA), Virax Biolabs Group (VRAX), TNF Pharmaceuticals (TNFA), and MyMD Pharmaceuticals (MYMD). These companies are all part of the "medical" sector. Akers Biosciences vs. VolitionRx Cardio Diagnostics ImmuCell OncoCyte Aspira Women's Health Trinity Biotech Biomerica Virax Biolabs Group TNF Pharmaceuticals MyMD Pharmaceuticals VolitionRx (NYSE:VNRX) and Akers Biosciences (NASDAQ:AKER) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, community ranking, profitability and media sentiment. Do analysts prefer VNRX or AKER? VolitionRx currently has a consensus target price of $3.75, indicating a potential upside of 454.82%. Given VolitionRx's stronger consensus rating and higher possible upside, equities analysts clearly believe VolitionRx is more favorable than Akers Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VolitionRx 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Akers Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings and valuation, VNRX or AKER? Akers Biosciences has higher revenue and earnings than VolitionRx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVolitionRx$1.29M48.71-$35.32M-$0.36-1.88Akers Biosciences$1.58M14.33-$3.89MN/AN/A Does the media prefer VNRX or AKER? In the previous week, VolitionRx had 1 more articles in the media than Akers Biosciences. MarketBeat recorded 1 mentions for VolitionRx and 0 mentions for Akers Biosciences. VolitionRx's average media sentiment score of 0.59 beat Akers Biosciences' score of 0.00 indicating that VolitionRx is being referred to more favorably in the media. Company Overall Sentiment VolitionRx Positive Akers Biosciences Neutral Which has more risk and volatility, VNRX or AKER? VolitionRx has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Akers Biosciences has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Do institutionals & insiders have more ownership in VNRX or AKER? 8.1% of VolitionRx shares are owned by institutional investors. Comparatively, 5.5% of Akers Biosciences shares are owned by institutional investors. 12.8% of VolitionRx shares are owned by insiders. Comparatively, 0.3% of Akers Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community favor VNRX or AKER? Akers Biosciences received 302 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 72.92% of users gave Akers Biosciences an outperform vote while only 11.36% of users gave VolitionRx an outperform vote. CompanyUnderperformOutperformVolitionRxOutperform Votes511.36%Underperform Votes3988.64% Akers BiosciencesOutperform Votes30772.92% Underperform Votes11427.08% Is VNRX or AKER more profitable? Akers Biosciences has a net margin of 0.00% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Akers Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets VolitionRx-2,321.14% N/A -163.39% Akers Biosciences N/A -87.42%-73.31% SummaryVolitionRx beats Akers Biosciences on 10 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Akers Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKER vs. The Competition Export to ExcelMetricAkers BiosciencesDiagnostic Substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.65M$2.51B$5.14B$9.08BDividend YieldN/A0.73%5.09%4.23%P/E RatioN/A6.0790.0517.18Price / Sales14.3375.121,116.25117.06Price / CashN/A15.0543.1037.85Price / Book0.253.284.784.78Net Income-$3.89M$29.98M$120.31M$225.60M Akers Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKERAkers BiosciencesN/A$1.36-7.5%N/A+496.5%$22.65M$1.58M0.004Gap DownVNRXVolitionRx1.7482 of 5 stars$0.67+18.6%$3.75+459.7%+4.3%$62.09M$770,000.00-1.5780Analyst ForecastGap UpCDIOCardio Diagnostics2.6575 of 5 stars$1.16-7.9%$2.00+72.4%-58.0%$46.91M$35,688.000.007Gap UpHigh Trading VolumeICCCImmuCellN/A$4.90-0.4%N/A-5.4%$43.67M$23.84M-9.8475OCXOncoCyte3.2612 of 5 stars$2.26-2.6%$4.42+95.4%-23.2%$38.04M$1.50M0.00120Analyst ForecastGap DownAWHAspira Women's Health1.2122 of 5 stars$0.76+0.7%$4.40+482.8%-69.7%$12.59M$9.15M-0.62110Analyst ForecastTRIBTrinity Biotech1.2087 of 5 stars$0.89-1.4%N/A-64.5%$6.80M$56.83M-0.39480News CoveragePositive NewsGap DownBMRABiomerica0.1423 of 5 stars$0.31-2.0%N/A-76.8%$5.17M$5.51M-0.8260Gap DownVRAXVirax Biolabs Group0.6869 of 5 stars$1.52-3.2%N/A+25.0%$4.91M$84,872.000.005News CoverageTNFATNF PharmaceuticalsN/A$1.08-6.0%N/AN/A$2.98MN/A0.006Gap DownMYMDMyMD PharmaceuticalsN/A$1.15-3.4%N/A-80.1%$2.73MN/A0.009 Related Companies and Tools Related Companies VolitionRx Alternatives Cardio Diagnostics Alternatives ImmuCell Alternatives OncoCyte Alternatives Aspira Women's Health Alternatives Trinity Biotech Alternatives Biomerica Alternatives Virax Biolabs Group Alternatives TNF Pharmaceuticals Alternatives MyMD Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AKER) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akers Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akers Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
